

Supplementary data for the article:

Terzić, N.; Konstantinović, J.; Tot, M.; Burojević, J.; Djurković-Djaković, O.; Srbljanović, J.; Štajner, T.; Verbić, T.; Zlatović, M.; Machado, M.; et al. Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials? *Journal of Medicinal Chemistry* **2016**, *59* (1), 264–281.
<https://doi.org/10.1021/acs.jmedchem.5b01374>

Supporting information-III**Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?**

Natasa Terzić,[#] Jelena Konstantinović,[¶] Mikloš Tot,[¶] Jovana Burojević,[¶] Olgica Djurković-Djaković,[∇] Jelena Srbljanović,[∇] Tijana Štajner,[∇] Tatjana Verbić,[¶] Mario Zlatović,[¶] Marta Machado,[§] Inês S. Albuquerque,[§] Miguel Prudêncio,^{§,*} Rick Sciotti,[†] Stevan Pecic,[∇] Sarah D'Alessandro,[‡] Donatella Taramelli,[‡] Bogdan A. Šolaja^{¶,*}

[#]Institute of Chemistry, Technology, and Metallurgy, Belgrade, Serbia

[¶]Faculty of Chemistry, University of Belgrade, Studentski trg 16, P.O. Box 51, 11158, Belgrade, Serbia

[∇]Institute for Medical Research, University of Belgrade, Dr.Subotića 4, 11129 Belgrade, Serbia

[§]Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal

[†]Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD20910, USA

[∇]Division of Experimental Therapeutics Department of Medicine, Columbia University, New York, NY 10032, USA

[‡]Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133 Milan, Italy

Table of contents

Inhibition potential of antiplasmodials 23 and 25 against the hERG K⁺ channel	III-S3
AMES mutagenicity screening of antiplasmodial 23	III-S4

Inhibition potential of antiplasmodials **23 and **25** against the hERG K⁺ channel.**

The experiments are performed on an IonWorksTM HT instrument (Molecular Devices Corporation), which automatically performs electrophysiology measurements in 48 single cells simultaneously in a specialized 384-well plate (PatchPlateTM). All cell suspensions, buffers and test compound solutions are at room temperature during the experiment. The cells used are Chinese hamster ovary (CHO) cells stably transfected with hERG (cell-line obtained from Cytomyx, UK). A single-cell suspension is prepared in extracellular solution (Dulbecco's phosphate buffered saline with calcium and magnesium pH 7-7.2) and aliquots added automatically to each well of a PatchPlateTM. The cells are then positioned over a small hole at the bottom of each well by applying a vacuum beneath the plate to form an electrical seal. The vacuum is applied through a single compartment common to all wells which is filled with intracellular solution (buffered to pH 7.2 with HEPES). The resistance of each seal is measured via a common ground-electrode in the intracellular compartment and individual electrodes placed into each of the upper wells.

Electrical access to the cell is then achieved by circulating a perforating agent, amphotericin, underneath the PatchPlateTM and then measuring the pre-compound hERG current. An electrode is positioned in the extracellular compartment and a holding potential of -80 mV applied for 15 sec. The hERG channels are then activated by applying a depolarizing step to +40 mV for 5 sec and then clamped at -50 mV for 4 sec to elicit the hERG tail current, before returning to -80 mV for 0.3 s.

Test compound is then added automatically to the upper wells of the PatchPlateTM from a 96-well microtitre plate containing a range of concentrations of each compound. Solutions are prepared by diluting DMSO solutions of the test compound into extracellular (final DMSO concentration 0.25%). The compound **23** (**25**) is left in contact with the cells for 300 s before recording currents using the same voltage-step protocol as in the pre-compound scan. Quinidine, an established hERG inhibitor, is included as a positive control and buffer containing 0.25% DMSO is included as a negative control. The results for all compounds on the plate are rejected and the experiment repeated if the IC₅₀ value for quinidine or the negative control results are outside quality-control limits. Each concentration is tested in 4 replicate wells on the PatchPlateTM. However, only cells with a seal resistance greater than 50 MOhm and a pre-compound current of at least 0.1 nA are used to evaluate hERG blockade. Post-compound currents are then expressed as a percentage of pre-compound currents and plotted against concentration for each compound. Where concentration-dependent inhibition is observed, the data are fitted to the following equation and an IC₅₀ value calculated:

$$y = \frac{y_{\max} - y_{\min}}{1 + (x/x_{50})^s} + y_{\min}$$

y = (post-compound current/pre-compound current) x 100; x = concentration; x_{50} = concentration required to inhibit current by 50% (IC₅₀) and s = slope of the graph.

Test Article	% Mean Inhibition						
	0 μ M	0.008 μ M	0.04 μ M	0.2 μ M	1 μ M	5 μ M	25 μ M
25	0	5.45	-9.95	12.4	-4.78	8.54	N/A
23	0	4.93	1.74	-0.24	0.35	11.7	N/A

AMES mutagenicity screening of antiplasmodial 23.

Approximately ten million bacteria are exposed in triplicate to compound **23** (six concentrations), a negative control (vehicle) and a positive control for 90 minutes in medium containing a low concentration of histidine (sufficient for about 2 doublings.) The cultures are then diluted into indicator medium lacking histidine, and dispensed into 48 wells of a 384 well plate (micro-plate format, MPF). The plate is incubated for 48 h at 37 °C, and cells that have undergone a reversion will grow in a well, resulting in a color change in wells with growth. The number of wells showing growth are counted and compared to the vehicle control. An increase in the number of colonies of at least two-fold over baseline (mean + SD of the vehicle control) and a dose response indicates a positive response. An unpaired, one-sided Student's T-test is used to identify conditions that are significantly different from the vehicle control.

Where indicated, S9 fraction from the livers of Aroclor 1254-treated rats is included in the incubation at a final concentration of 4.5 %. An NADPH-regenerating system is also included to ensure a steady supply of reducing equivalents.

Strains used in this study:

S. typhimurium TA98: hisD3052, rfa, uvrB / pKM101; detects frame-shift mutations.

S. typhimurium TA100: hisG45, rfa, uvrB / pKM101; detects base-pair substitutions.